Shares of Bajaj Healthcare Ltd hit 20% higher circuit on 17 January after the corporate introduced securing unique licensing rights to market Magnesium L Threonate in India.
In its regulatory submitting, the corporate mentioned that they’ve secured unique rights from Threotech LLC to fabricate, distribute, and promote the completed formulation of Magnesium L Threonate (Magtein) in India.
Moreover, the corporate will acquire alternatives to determine advertising partnerships with outstanding pharmaceutical companies in India. Bajaj Healthcare, which already provides the API for Magtein within the US, the place the model generates roughly USD 438 million in gross sales, will now develop its footprint within the Indian market.
This improvement additional bolsters Bajaj Healthcare’s status as a dependable companion within the pharmaceutical sector, leveraging its strong home presence and manufacturing experience to capitalize on the rising demand for Magnesium L-Threonate in India.
At 3:30 pm, the shares of Bajaj Healthcare closed 20% increased at Rs 673.85 on NSE.
Uncover the subsequent massive funding! Unicorn Indicators’ IPO screener helps you establish promising preliminary public choices. Obtain Unicorn Indicators and get forward of the curve! Signal Up Now & Discover Your Subsequent IPO Gem!
